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BMP receptors determine the intensity of BMP
signals via Smad1 C-terminal phosphorylations.
Herewe show that a finely controlled cell biolog-
ical pathway terminates this activity. The dura-
tion of the activated pSmad1Cter signal was
regulated by sequential Smad1 linker region
phosphorylations at conserved MAPK and
GSK3 sites required for its polyubiquitinylation
and transport to the centrosome. Proteasomal
degradation of activated Smad1 and total polyu-
biquitinated proteins took place in the centro-
some. Inhibitors of the Erk, p38, and JNK
MAPKs, as well as GSK3 inhibitors, prolonged
the duration of a pulse of BMP7. Wnt signaling
decreased pSmad1GSK3 antigen levels and re-
distributed it from the centrosome to cytoplas-
mic LRP6 signalosomes. In Xenopus embryos,
it was found that Wnts induce epidermis and
that this required an activeBMP-Smadpathway.
Epistatic experiments suggested that the dorso-
ventral (BMP) and anteroposterior (Wnt/GSK3)
patterning gradients are integrated at the level
of Smad1 phosphorylations during embryonic
pattern formation.
INTRODUCTION
Understanding how cells integratemultiple signaling path-
ways to achieve specific cell differentiations is one of the
major challenges in cell and developmental biology. Em-
bryonic patterning in Xenopus is regulated by gradients
of growth factors and their antagonists, with bone mor-
phogenetic proteins (BMPs) controlling dorsal-ventral (D-V)
and Wnt signals anterior-posterior (A-P) cell fates (Niehrs,980 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc.2004). This positional information must be seamlessly inte-
grated, for when a blastula is cut in half, the embryo can
self-regulate, forming perfect identical twins (De Robertis,
2006). In the ectoderm, the main cell differentiation deci-
sion is between neural and epidermal tissues, for which
excellent molecular markers exist. Neural tissue differenti-
ates when BMP signaling is inhibited by BMP antagonists
or depletion by anti-BMPmorpholino (MO) oligos, whereas
epidermis is formed at high BMP signaling levels (Harland,
2000; Reversade and De Robertis, 2005). BMP receptors
(BMPR) are serine/threonine protein kinases that signal
by phosphorylating the transcription factors Smad1/5/8
at C-terminal sites (SS[PO3]VS[PO3]), causing their activa-
tion and nuclear translocation (Shi and Massague´, 2003;
Feng and Derynck, 2005).
Neural tissue can also be induced by receptor tyrosine
kinases (RTKs) such as FGF and IGF receptors via the
activation of mitogen-activated protein kinase (MAPK)
(reviewed in Wilson and Edlund, 2001; De Robertis and
Kuroda, 2004; Stern, 2005). This neural-inducing activity
can be explained in part by an inhibitory phosphorylation
in the linker (middle) region of Smad1 at four conserved
MAPK (PXS[PO3]P) sites (Pera et al., 2003; Kuroda
et al., 2005). This linker region MAPK phosphorylation
was first discovered in cultured cells treated with EGF
(Kretzschmar et al., 1997) and recently reported to pro-
mote polyubiqutinylation of Smad1 by the Smurf1 E3-
ubiquitin ligase (Zhu et al., 1999; Sapkota et al., 2007),
a finding independently confirmed here. FGF/MAPK sig-
nals are known to oppose BMP/Smad1 in many develop-
ing organs (De Robertis and Kuroda, 2004). Remarkably,
mouse phosphorylation-resistant mutations in the MAPK
sites of Smad1, introduced by homologous knock-in,
generated embryonic fibroblasts in which the transcrip-
tional activation of a reporter gene by BMP becomes
resistant to repression by addition of FGF (Aubin et al.,
2004; Sapkota et al., 2007). Thus, the role of Smad1 as
an interface for integrating RTK and BMP signals is firmly
established.
Although less generally recognized, the Wnt signaling
pathway also influences neural induction. Wnts play mul-
tiple roles during development: at the early blastula stage,
canonical Wnt signaling provides a dorsalizing signal via
activation of xTcf3 (Harland, 2000; Heasman, 2006), and
at the neurula stage, it regulates neuronal differentiation
via inhibition of NeuroD (Marcus et al., 1998). At the gas-
trula stage, overexpression of Wnt8 causes antineural
effects in Xenopus (Christian andMoon, 1993).Wnt antag-
onists such as Dickkopf-1 (Dkk1) and secreted Frizzled-
related proteins (sFRPs), promote neural differentiation
in Xenopus, chick, and mouse ES cells (Glinka et al.,
1998; Wilson and Edlund, 2001; Aubert et al., 2002). The
canonical Wnt pathway signals through the inhibition of
glycogen synthase kinase 3 activity (Logan and Nusse,
2004). GSK3 is a protein kinase that usually requires pre-
phosphorylated substrates, phosphorylating Ser/Thr resi-
dues located four amino acids upstream of sites primed
by other kinases (Cohen and Frame, 2001). Frequently,
as in the case of b-catenin, such coupled phosphoryla-
tions by two protein kinases are followed by polyubiquiti-
nation and degradation in the proteasome (Liu et al., 2002;
Cohen and Frame, 2001). This project was initiated when
we noticed conserved GSK3 sites in vertebrate Smad1/5/
8 proteins that could be phosphorylated by GSK3 after
priming by MAPK. This was exciting, because a pathway
in which
DkkxWntxGSK3xpSmad1CterxNeural plate
could potentially explain the proneural effects of anti-
Wnts.
In the present study, we demonstrate that phosphoryla-
tion at the GSK3 sites represses the transcriptional activity
of Smad1 by enhancing proteasomal degradation of
pSmad1Cter. We found that GSK3 phosphorylation is an
essential requirement for polyubiquitination. Pulse-chase
experiments with BMP7 revealed a novel cellular pathway
that regulates the duration of the BMP signal. First, BMPR
causes C-terminal phosphorylation (pSmad1Cter) and
nuclear translocation. Next, the pSmad1MAPK phosphory-
lation is mediated by MAPK enzymes (Erk, p38, and JNK)
in the nucleus. Subsequently, GSK3 recognizes the pre-
phosphorylated linker region, generating pSmad1GSK3 at
an unknown cellular location. The triply phosphorylated
protein is transported along microtubule-like structures
to the centrosome. The centrosome is the cellular location
at which proteasomes normally accumulate in many
cell types (Badano et al., 2005). The GSK3 activity that
phosphorylates Smad1 was regulated by Wnt3a protein
addition in cultured cells, leading to the accumulation of
pSmad1Cter. A constitutively active low-density lipopro-
tein receptor-related protein 6 (CA-LRP6) caused redistri-
bution of pSmad1GSK3 from the centrosome to cytoplas-
mic particles resembling the recently described LRP6
signalosomes (Bilic et al., 2007). In vivo epistatic experi-
ments indicated that Smad1 phosphorylations by GSK3
play a key role in mediating the effects of Wnt signalingCon neural development at the gastrula stage. In dissoci-
ated ectodermal cells, overexpression of Wnt8 and its
coreceptor LRP6 induced epidermal differentiation in a
Smad1/5/8-dependent manner. The results suggest that
a branch of the canonical Wnt pathway signals through
the stabilization of BMP-Smad signals.
RESULTS
GSK3 Phosphorylation Inhibits Smad1 Function
Inspection of the Smad1 sequence revealed four GSK3
sites located four amino acids upstream of the PXSP
Erk/MAPK sites in the linker region (Figure 1A). These
potential GSK3 sites were conserved in BMP-responsive
Smad1/5/8 across vertebrates and in Drosophila Mad
(Figure S1 in the Supplemental Data available online).
Phosphorylation-resistant mutations (Ser/Thr to Ala) were
introduced into a human Smad1 expression construct
(Kretzschmar et al., 1997) previously characterized in Xen-
opus embryos (Pera et al., 2003; Kuroda et al., 2005).
These sites were mutated individually or in combination;
strongest effects were found when all four GSK3 sites
were mutated (data not shown) in a construct designated
SGM (Figure 1B). The phenotypic effects of SGM were
compared to those of Smad1 wild-type (SWT) and
Smad1 mutated at the MAPK sites (designated SMM).
Overexpression of mRNA encoding GSK3 or MAPK phos-
phorylation-resistant mutants in early Xenopus embryos
resulted in hyperactive Smad1 proteins that caused
strongly ventralized phenotypes, as indicated by tran-
script accumulation of the BMP-inducible marker Sizzled
(Figures 1C–1F). A constitutively active phospho-mimetic
form of Smad1, in which the C-terminal SVS phosphoryla-
tion sites were mutated into EVE (designated SEVE;
Figure 1G), provided a novel reagent independent of
BMPR signaling (compare Figure 1D to Figure 1H).
GSK3 and MAPK phosphorylation-resistant mutants of
SEVE strongly induced Sizzled, not only ventrally but
also ectopically in the floor plate (Figures 1I and 1J, insets).
We conclude that the function of the putative GSK3 phos-
phorylations in vivo, like those of MAPK, is to downregu-
late Smad1 activity.
We next tested whether Smad1 was a substrate for
GSK3 that required priming by MAPK (Cohen and Frame,
2001). The entire linker region of human Smad1 was
tagged with six histidines, expressed in E. coli, and puri-
fied. In vitro phosphorylations were performed in two
stages, and it was found that GSK3b caused the incorpo-
ration of [g-32P]ATP by Smad1 linker protein, but only after
prephosphorylation by Erk/MAPK (Figure 1K, compare
lanes 2 and 4).
Antibody reagents specific for human phospho-
Smad1GSK3 (p-Serine 210) and phospho-Smad1MAPK
(p-Serine 214) were developed. A synthetic peptide
(SS[PO3]DPGS[PO3]PFQMPADT) proved extremely anti-
genic. After affinity purification on a column of the same
peptide phosphorylated only in Ser214, one rabbit pro-
duced a very high titer antibody for pSmad1MAPK, suchell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 981
Figure 1. Smad1 Is Phosphorylated and Inhibited by GSK3
(A) Smad1 contains MAPK (blue) and GSK3 (red) phosphorylation sites in its linker region. The PPAY binding site of Smurf1 is boxed and serines 210
and 214 used to raise antibodies indicated by asterisks.
(B) Smad1 constructs encoding Smad1 wild-type (SWT) or phosphorylation-resistant mutants for GSK3 (SGM) and MAPK (SMM) sites.
(C–F) Injection of SGM or SMM, but not of SWT, mRNA increased expression of the ventral marker sizzled in Xenopus embryos.
(G) A BMP-independent phospho-mimetic activated Smad1 (SEVE) in which the SVS terminus was mutated into EVE.
(H–J) Activity of SEVE is increased by phosphorylation-resistant linker mutations.
(K) GSK3 radioactively phosphorylates Smad1 in vitro, but only when primed byMAPK. The recombinant Smad1 linker substrate was about 90%pure
in polyacrylamide gels (data not shown).
(L and M) Phospho-specific antibodies for hSmad1 Ser214 (pSmad1MAPK) and Ser210 (pSmad1GSK3 antibody B was used).
(N) Phospho-specific antibodies (pSmad1MAPK and pSmad1GSK3-A) demonstrate that GSK3 phosphorylation of recombinant Smad1 requires MAPK
priming, in nonradioactive Western blots. Recombinant Smad1 substrate was used in the same amount as in (K).that it detected overexpressed hSmad1-wt, but not the
phosphorylation-resistant mutant S214A, at dilutions of
1:200,000 (Figure 1L). A second rabbit produced a phos-
pho-specific antibody for pSmad1GSK3 Ser210 active at
dilutions of 1:30,000 after affinity depletion with phos-
pho-Ser214 peptide and positive purification with phos-
pho-Ser210 peptide (antibody A). An additional anti-
pSmad1GSK3 Ser210 (antibody B), derived with peptide
PHSPTSS[PO3]DPGSPFQ as antigen, detected overex-
pressed hSmad1-wt but not the phosphorylation-resistant
mutant S210A (Figure 1M). Immunoblots of nonradioac-
tive biochemical reactions confirmed that Ser214 in982 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Increcombinant Smad1 protein was indeed phosphorylated
by Erk/MAPK and that the phosphorylation of Ser210 by
GSK3 was strongly dependent on prephosphorylation by
MAPK and underscored the phospho-specificity of our
antibodies (see Figure 1N, lanes 2–4). We conclude that
Smad1 is phosphorylated by GSK3 in vitro in a MAPK-
dependent fashion.
GSK3 phosphorylations were required for the polyubi-
quitinylation of Smad1 (Figure 2A). The Smad ubiquitina-
tion regulatory factor 1 (Smurf1) E3 ubiquitin ligase binds
to a PPXY sequence (Zhu et al., 1999) located near the
Smad1 linker MAPK phosphorylation sites (Figure 1A)..
Figure 2. GSK3 and MAPK Phosphorylation Sites Regulate Polyubiquitinylation of Smad1 and Its Transcriptional Activity
(A) Polyubiquitinylation of Smad1 requires GSK3 and MAPK phosphorylation sites. Cells were cotransfected with Smad1-flag, Smurf1, and
Ubiquitin-HA.
(B) GSK3 inhibitors decrease polyubiquitinylation of human Smad1. SB415286 (SB4, Biomol) was used at 40 mM, and LiCl at 30 mM, for 24 hr.
(C) SGM and SMM are more active than SWT mRNA in a BRE-luciferase transcriptional reporter assay in ectodermal Xenopus explants.
(D) The GSK3 inhibitor LiCl increases BMP4-induced transcriptional activation of BRE-luciferase in 293T cells 8 hr after cotransfection. Data are rep-
resented as mean ± standard deviation, three independent experiments.We used the assay of Zhu et al. (1999) in 293T cells, in
which flag-tagged Smad1-WT or its GSK3 or MAPK
mutants were cotransfected with HA-tagged ubiquitin
and Smurf1, and Smad1 was immunoprecipitated via its
flag-tag. Polyubiquitinylation of GSK3 orMAPK phosphor-
ylation-resistant Smad1 proteins (SGM and SMM) was
greatly reduced when compared to their wild-type coun-
terpart (Figure 2A, lanes 2–4). The mono- or diubiquitiny-
lated forms were less affected. In addition, polyubiquitiny-
lation of SWT in 293T cells was inhibited by the GSK3
inhibitors SB415286 or lithium chloride (LiCl) (Figure 2B).
We conclude that phosphorylation of Smad1 by GSK3 is
essential for its polyubiquitinylation in cultured mamma-
lian cells.
We next tested whether the transcriptional activity of
Smad1 was regulated by GSK3 phosphorylations. Exper-
iments were performed in Xenopus ectodermal explants,
which have physiological endogenous BMP signaling
levels sufficient for reporter gene studies (Kuroda et al.,
2005). It was found that the phosphorylation-resistant
mutants SGM and SMM caused significantly stronger
induction (3- to 4-fold) of a BMP reporter (BREx2-Id1-lucif-
erase; Korchynskyi and ten Dijke, 2002) than SWT
(Figure 2C). In addition, the effect of the GSK3 inhibitor
LiCl on BMP-dependent transcription was tested. Co-
transfection of BMP4 and BREx2-Id1-luciferase DNAs
into 293T cells showed that LiCl treatment significantly
increased the transcriptional activity of endogenous
BMP-Smads (Figure 2D). These results were congruent
with the microinjection of SGM and SEVE-GM mRNAs in
Xenopus embryos (Figures 1E and 1I) and suggested
that GSK3 activity normally represses Smad1 signaling
by promoting proteasomal degradation.CGSK3 and MAPKs Regulate the Duration
of BMP Signals
Wenext investigatedwhether the coupled inhibitory phos-
phorylations byMAPK andGSK3 regulated the duration of
the BMP7 signal in pulse-chase experiments (Figure 3).
The intensity of the Smad1 signal is determined by the
levels of C-terminal phosphorylation (pSmad1Cter) by
BMPR (Feng and Derynck, 2005). The phosphorylations
of endogenous Smad were analyzed in L cells, which
respond particularly well to BMP in serum-free medium
(serum complicates analyses because it contains BMP
and FGFs). Note that in these and all subsequent cultured
cell experiments, endogenous Smad1 was analyzed. By
using this assay, we found that theMAPK andGSK3 phos-
phorylations were triggered by BMPR activity.
A strong pSmad1Cter signal was elicited at time 0 after a
15 min pulse of 5 nM BMP7 (Figure 3A, compare lanes 1
and 2), which partially decreased after 1 hr and greatly
diminished by 2.5 hr (lanes 3–5). Interestingly, pSmad1MAPK
antibodies also detected a BMP7-induced band, but with
a 0.5 hr delay. The pSmad1GSK3 antibody detected BMP-
induced phosphorylations 0.5 and 1 hr after treatment,
which decreased by 2.5 hr (Figure 3A, lanes 2–5). Total
Smad1 protein levels did not change during this period;
this is in agreement with observations that only a small
fraction of the total Smad1 is phosphorylated at physio-
logical BMP levels, with a large reservoir of inactive
Smad1 persisting at most times (e.g., Kuroda et al.,
2005). BMP treatment does not increase activity levels
of the three main cellular MAPKs (Erk, p38, and JNK)
(Kuroda et al., 2005; Sapkota et al., 2007; data not shown).
Experiments with chemical inhibitors (U0126 for MEK/Erk,
Calbiochem CFPD inhibitor for p38, SP600125 for JNK)ell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 983
Figure 3. The Duration of the pSmad1Cter Signal Is Regulated by MAPK and GSK3
(A) Sequential phosphorylation of Smad1 by BMPR, MAPK, and GSK3 after a pulse of BMP7.
(B) Induction of pSmad1MAPK by BMP7 is blocked by triple inhibition of MAPKs (lane 7). Inhibitors used were: MEK/Erk (10 mM U0126), p38 (10 mM
Calbiochem CFPD p38 inhibitor), and JNK (25 mM SP600125). Lane 6 contained both p38 and JNK inhibitors.
(C) The duration of pSmad1Cter signal is prolonged by inhibition of MAPKs, GSK3 (40 mM SB415286 or 30 mM LiCl), or proteasome activity (50 mM
lactacystin).showed that the Smad1 MAPK phosphorylation triggered
by BMP7 results from the combined constitutive activity of
these threeMAPKs in cultured cells (Figure 3B; Figure S2).
We have also observed, with a phosphorylation-resistant
C-terminal mutant, that MAPK and GSK3 can phosphory-
late Smad1 in a BMPR-independent fashion (data not
shown); this activity may help explain why neural induction
by Chordin requires an intact MAPK pathway (Pera et al.,
2003). Recently, Sapkota et al. (2007) reported that BMP
induced MAPK phosphorylation, but suggested the in-
volvement of a different and as yet unknown kinase; how-
ever, they did not test a cocktail of the three inhibitors as in
Figure 3B (lane 7). We conclude from these pulse-chase984 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc.experiments that BMP treatment triggers three sequential
phosphorylations in Smad1: first by BMPR, second by
MAPKs, and third by GSK3.
The sequential nature of these events suggested that
they might function in the regulation of the duration of the
BMP signal, which would be terminated by the coupled
activity of MAPK and GSK3 via degradation in the protea-
some. To test this hypothesis, we performed BMP7 pulse-
chase experiments in the presence of the MAPK inhibitor
cocktail, the GSK3 inhibitors LiCl or SB415286, or the pro-
teasome inhibitor lactacystin. As shown in Figure 3C, all
these treatments significantly increased the duration of
the pSmad1Cter signal. These results suggest a molecular
Figure 4. MAPK and GSK3 Phosphoryla-
tions Target Smad1 and Total Polyubi-
quitinated Proteins to the Centrosome
in Cos7 Cells
(A–C) pSmad1Cter accumulates in the centro-
some (arrows) in response to proteasomal inhi-
bition by lactacystin (24%, n = 323).
(D) The proteasomal subunit S20a5 normally
accumulates in the centrosome in Cos7 cells
(arrows).
(E and F) Nuclear and centrosomal localization
of pSmad1MAPK.
(G–I) pSmad1GSK3-A (green) colocalizes with
the centrosome marker g-Tubulin (red). Note
that in (E) through (I), BMP4 was not added,
but the medium contained 10% fetal calf se-
rum, which provides growth factors such as
BMP and FGF.
(J and K) Specificity of pSmad1MAPK and
pSmad1GSK3-A staining: phospho-peptide
competition and l-phosphatase sensitivity.
(L) pSmad1GSK3 accumulates in the centro-
some 8 hr after lactacystin (50 mM) treatment
(a 25-fold increase in volume).
(M–O) Treatment of Cos7 cells with lactacystin
induces accumulation of total cellular polyubi-
quitinylated proteins in the centrosomal region
marked by pericentrin in red. In one cell, a ring
of pericentrosomal staining is seen.pathway in which, after phosphorylation by BMPR, the
duration of the pSmad1Cter signal is controlled by coupled
MAPK and GSK3 phosphorylations and protein degrada-
tion in the proteasome.
pSmad1MAPK/GSK3 Is Targeted to the Centrosome
Unexpectedly, when the subcellular localization of the var-
ious forms of phosphorylated Smad1 in cultured cells was
examined, it was found that Smad1 targeted for degrada-
tion accumulated in the centrosomal region (Figure 4). The
pSmad1Cter antigen accumulates in the nucleus of Cos7
cells after BMP4 treatment in serum-free conditions, but
we noted that in cells treatedwith the proteasome inhibitorClactacystin, pSmad1Cter was also found in a cytoplasmic
region (Figures 4B and 4C) that appeared to correspond
to the centrosome (when a kidney-shaped nucleus is
present, as in Figure 4C, the centrosome is almost invari-
ably located in its concavity; Wilson, 1928). The centro-
some, the region of cytoplasm that surrounds the centri-
oles, is a center for ubiquitin-mediated proteolysis in
which the proteasomal machinery becomes concentrated
(Badano et al., 2005). We corroborated this by staining
Cos7 cells with proteasomal S20a5 subunit antibodies.
Proteasomes were present both in nucleus and cyto-
plasm, but were more concentrated in the centrosome
(Figure 4D, arrows).ell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 985
Phospho-Smad1MAPKwas observed both in the nucleus
and in a bright centrosome-like body in the cytoplasm (Fig-
ures 4E and 4F). The pSmad1GSK3 antibody stained the
nucleusweakly and thecytoplasmstrongly, alongmicrotu-
bule-like filaments that converged on the centrosome,
which was unequivocally identified by colocalization with
the established centrosomal marker g-tubulin (Figures
4G–4I). Specificity controls showed that centrosomal
phospho-Smad1 staining was eliminated or reduced by
competition with the corresponding phosphorylated pep-
tide (Figure 4J), by l-phosphatase treatment (Figure 4K),
and by the MAPK inhibitor cocktail or the GSK3 inhibitor
SB415286 (Figure S2). Centrosomal localization was
greatly enhanced by treatment of Cos7 cells with the pro-
teasomal inhibitor lactacystin (Figure 4N), supporting the
view that Smad1 is degraded by proteasomes located in
the centrosome.
Finally, we investigatedwhether this cellular mechanism
represented a wider phenomenon that might apply to
other proteins targeted for degradation. An antibody
against total polyubiquitin chains stained diffusely both
nucleus and cytoplasm (Figure 4M), but after lactacystin
treatment, polyubiquitin antigen became clearly concen-
trated in the pericentrosomal region overlapping, and in
some cases surrounding, the Pericentrin centrosomal
marker (Figures 4N and 4O). We conclude that the cellular
degradation pathway we have identified probably is used
by many other proteins marked for destruction in addition
to Smad1, because total polyubiquitinylated proteins also
became concentrated in centrosomes when proteasome
activity was inhibited.
Smad Degradation Is Regulated by Wnt
As shown in the model in Figure 5A, the experiments pre-
sented so far suggest that an elaborate cellular regulatory
pathway is involved in the termination of BMP signaling.
Nuclear C-terminal phosphorylated Smad1 is subjected
first to MAPK phosphorylation in the linker region and
then to GSK3 phosphorylation, triggering the polyubiquiti-
nylation of Smad1. Once targeted for degradation, Smad1
is transported, probably along microtubules, to the cen-
trosome, where the triply phosphorylated and polyubiqui-
tinylated Smad1 is degraded by proteasomes. A key
question, with important implications for the integration
of patterning signals, is whether GSK3 phosphorylation
of Smad1 is regulated by canonical Wnt signaling.
To investigate this, the effects of treating cultured L cells
(in the absence of serum and in the presence of BMP7 and
FGF2) with purified Wnt3a protein were examined. The
levels of pSmad1GSK3 were decreased, but not eliminated,
1 hr after Wnt3a addition, while the levels of pSmad1Cter
increased (Figure 5B). The increase in pSmad1Cter was
due to stabilization, rather than to secondary induction
of BMP ligands, because transfection of b-catenin DNA
(both in wild-type and stabilized mutant forms) did not
significantly affect pSmad1Cter phosphorylation levels in
L cells (data not shown). Wnt3a protein also affected
Smad1 phosphorylations in human embryonic stem cells986 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc.(hESCs), causing pSmad1GSK3 to decrease moderately
and pSmad1Cter to accumulate (Figure 5C). We conclude
that the levels of pSmad1Cter are stabilized by Wnt3a
treatment, in agreement with the pathway proposed in
Figure 5A.
We next investigated whether the activation of Wnt sig-
naling caused a change in the cellular localization of the
pSmad1GSK3 antigen. A recent study has demonstrated
that Wnt signals cause the colocalization of components
of the b-Catenin degradation complex, such as GSK3
and Axin, with intracellular membrane vesicles containing
the Wnt receptor LRP6 (Bilic et al., 2007). Transfection of
CA-LRP6 DNA (Tamai et al., 2004) into Cos7 cells caused
a dispersion of the centrosomal pSmad1GSK3 antigen into
small cytoplasmic particles when compared to untrans-
fected cells (Figures 5D and 5E). These cytoplasmic
puncta most likely correspond to LRP6 signalosomes
(Bilic et al., 2007) because they colocalized with endoge-
nous GSK3 protein (Figure 5G). In addition to dispersing
the centrosomal material into smaller particles, CA-LRP6
caused the pSmad1GSK3 antigen to accumulate in the
cell nucleus (Figures 5D–5G). Perhaps transport to the
centrosome is required for nuclear export of Smad1
marked for destruction. We conclude that activation
of the Wnt pathway triggers a major redistribution of
Smad1 forms targeted for degradation within the cell.
We next turned to the Xenopus embryo. An old enigma
is why overexpression of Wnt antagonists, such as Dkk1,
cause dorsalized phenotypes (expanded neural plate at
the expense of epidermis) almost indistinguishable to
those of embryos microinjected with BMP antagonists,
such as Chordin protein (Figures 6A–6C). This suggested
the possibility that Wnt inhibitors might regulate BMP
signaling at gastrula through the pathway indicated in
Figure 6D. This hypothesis was tested by coinjection of
Dkk1 and Xenopus BMP4 mRNA (Figures 6E–6H). BMP4
overexpression inhibited expression of the forebrain/eye
marker Rx2a, and Dkk1 mRNA blocked this inhibition
(compare Figures 6G and 6H). Dkk1 is one of the strongest
and best characterized inhibitors of canonical Wnt signal-
ing, which functions by removing the LRP6 Wnt corecep-
tor from the cell surface (Glinka et al., 1998; Niehrs, 2004).
Therefore, in principle, Dkk1 should not have inhibited
BMP4 signaling.
To explore this in vivo in aWnt loss-of-function situation,
we used a previously characterized Xenopus laevis Wnt8
MO (Lee et al., 2006). xWnt8 is the main Wnt expressed
posteriorly during gastrulation (Christian and Moon,
1993), and its knockdown causes dorsalization with ex-
pansion of brain at the expense of epidermis (marked by
Cytokeratin) (Figures 6J and 6N). Microinjection of wild-
type Smad1mRNA had little effect on the xWnt8 depletion
phenotype (Figures 6K and 6O), yet injection of the same
amount of SGMmRNA was able to abrogate the dorsaliz-
ing effects of Wnt8 MO (Figures 6L and 6P). This indicates
that the GSK3 phosphorylation sites in microinjected
Smad1 play a crucial role in the dorsalizing effects caused
by Wnt8 depletion. The phosphorylation of Smad1 GSK3
Figure 5. Wnt3a Regulates Smad1 Phosphorylation
(A) Model of biochemical and cellular signaling pathway integration at the level of Smad1 phosphorylations.
(B) Wnt3a protein (300 ng/ml, R&D Systems) inhibits Smad1 phosphorylation by GSK3 and stabilizes pSmad1Cter. L cells cultured in the absence of
serum were treated with purified Wnt3a protein for 1 hr; 0.3 nM BMP7 and 40 ng/ml FGF2 were added after 20 min of Wnt treatment.
(C) Wnt3a (300 ng/ml) stabilizes pSmad1Cter and b-Catenin in hESCs after 2 hr.
(D and E) Activation of the Wnt pathway with transfected CA-LRP6 (Tamai et al., 2004) disperses pSmad1GSK3 from the centrosome into small cy-
toplasmic puncta. Note that in CA-LRP6-transfected cells, the levels of pSmad1GSK3 in the nucleus are elevated.
(F andG) The cytoplasmic puncta containing pSmad1GSK3most likely correspond to LRP6 signalosomes because they costain with GSK3 antibodies.
Transfected cells were identified by cotransfection of CFP, not shown here.sites requires MAPK priming and, in agreement with this,
phosphorylation-resistant SMM, but not SWT mRNA, also
inhibited the effects of Wnt8 MO in the embryo (Figure S3).
Dkk1 overexpression is expected to block all canonical
Wnt signaling at gastrula. Dkk1 mRNA microinjection
expanded the neural plate, and overexpressed wild-type
Smad1 was ineffective at counteracting this (Figures
6Q–6S), whereas the GSK3 phosphorylation-resistant
mutant SGM was able to reverse the enlargement of the
neural plate produced by Dkk1 mRNA (compare Figures
6S and 6T). These epistatic experiments support the hy-
pothesis that the GSK3 phosphorylation sites in Smad1
are critical targets of Dkk1 andWnt8 signaling during Xen-
opus development.CThe Antineural Effects of Wnt/GSK3 Require
Smad1 but Not Tcf3
We next investigated the molecular pathway by which
Wnt/GSK3 regulates the decision between epidermal
and neural cell fates in vivo. In Xenopus, it is sufficient to
dissociate ectodermal (animal cap) cells to switch from
an epidermal to a neural fate (Wilson and Hemmati-Bri-
vanlou, 1995). This default neural differentiation is caused
by sustained activation of MAPK/Erk (Kuroda et al., 2005).
Ectodermal explants normally differentiate into epidermis,
while dissociated animal cap cells form neural tissue
(Figure 7A, compare lanes 2 and 3). LiCl, an inhibitor of
GSK3, inhibits neural tissue and causes epidermal differ-
entiation (Figure 7A, lanes 3–6).ell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 987
Figure 6. The Dorsalizing Effects of Wnt
Inhibition Are Rescued by SGM
(A–C) Dkk1 (n = 28) and Chordin (n = 45) protein
(R&D) injections into the blastula cavity (60 nl of
2.5 mM and 0.5 mM, respectively) present con-
siderable phenotypical similarities.
(D) Proposed molecular pathway.
(E–H) Dkk1 mRNA suppresses the antineural
phenotype of BMP4 overexpression (n for
each sample was 18, 13, 23, and 18, respec-
tively).
(I–P) Wnt8 MO causes dorsalization, which is
blocked by GSK3-resistant SGM, but not by
SWT mRNA (n for each sample was 22, 17,
23, and 26, respectively).
(Q–T) The expansion of the neural plate by
Dkk1 mRNA is rescued by GSK3-resistant
SGM, but not SWT mRNA (n = 30, 22, 21,
and 27, respectively).Microinjection of pCSKA-Wnt8 and pCS2-LRP6 DNA,
which are expressed at gastrula stage (Christian andMoon,
1993), induced epidermis 8-fold in dissociated animal cap
cells (Figure 7B). Importantly, epidermal induction by Wnt
was blocked by coinjection of mRNA encoding a domi-
nant-negative Smad5 mutant mimicking the zebrafish
somitabun mutant (mouse DN-Smad5; Beck et al., 2001)
that blocks all BMP/Smad1/5/8 signaling (Figure 7B).988 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc.The epidermal-inducing effect of Wnt8/LRP6 DNA, which
was in itself a novel observation, was not caused by an
increase of BMP4mRNA levels, which did not change sig-
nificantly when compared to uninjected cells (mean 0.9 ±
0.2 standard deviation) in the same samples. This is in
agreement with previous work in Xenopus showing that
xWnt8 is unable to induce BMP4 (Hoppler and Moon,
1998). In whole embryos, DN-Smad5 eliminated epidermal
Figure 7. Wnt Signaling Induces Epidermis in a Smad1/5/8- and b-Catenin-Dependent, but Tcf3-Independent, Manner
(A) LiCl induces epidermis (Cytokeratin) and inhibits neural differentiation (NCAM, Otx2). Radioactive RT-PCR analysis of whole embryos (WE), animal
cap (AC) explants, and dissociated animal cap cells at stage 13. MyoD indicates lack of mesoderm induction and Ornithine decarboxylase (ODC)
equal loading.
(B) Quantitative PCR of dissociated animal caps injected with pCSKA-Wnt8 and pCS2-LRP6 DNA. DN-Smad5 mRNA was coinjected to block
Smad1/5/8 activity. Cytokeratin mRNA levels at stage 13 were normalized for ODC mRNA, and the standard deviation from three independent ex-
periments is indicated.
(C and C0) Wnt3a protein (60 nl of 16 ng/ml) microinjected into the blastula cavity at stage 9 inhibits anterior neural plate and expands epidermis (n = 40
and 42, respectively).
(D and D0) DN-Smad5 converts the entire ectoderm into neural tissue and is epistatic to Wnt3a protein injection (n = 27 and 35). ADMP MO was co-
injected to eliminate all traces of epidermis.
(E and E0) Dkk1 mRNA expands the neural plate (n = 100 and 53).
(F) DN-Tcf3 mRNA eliminates the neural plate; only a ring of Sox2 expression in ventral mesoderm remained (90%, n = 30).
(F0) Dkk1 mRNA rescues neural plate in the presence of DN-Tcf3 in 60% of embryos (n = 70).
(G and G0) The induction of neural plate by Dkk1 mRNA has a complete requirement for b-Catenin (100%, n = 17 and 55, respectively).
(H) Model in which the BMP (D-V) andWnt (A-P) patterning pathways are integrated at the level of Smad1/5/8 phosphorylations. Black arrows indicate
direct protein-protein interactions and blue arrows transcriptional regulation by Smad1/5/8; all interactions are supported by overexpression or mor-
pholino studies in Xenopus (Lee et al., 2006, and data not shown).differentiation, causing ubiquitous neural differentiation of
the entire ectoderm (particularly in the presence of MO
for ADMP, a BMP expressed at low Smad1/5/8 signaling
levels; Figures 7C and 7D; Reversade and De Robertis,
2005). Microinjection of Wnt3a protein at late blastula ex-Cpanded the embryonic epidermis but was without effect
in a DN-Smad5 background (Figures 7C0 and 7D0). Simi-
larly, GSK3 MO, which expands epidermis and inhibits
neural tissue in the whole embryo, was unable to induce
epidermis in DN-Smad5 embryos (Figure S4).We concludeell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 989
that Wnt/GSK3 signals induce epidermis in Xenopus em-
bryos and that this requires an active BMP/Smad1/5/8
pathway.
The canonical Wnt pathway signals by preventing the
degradation of b-Catenin, an adaptor protein containing
armadillo repeats, which accumulates in the nucleus,
binds to the repressor T cell factor 3 (Tcf3), and activates
the transcription of Tcf target genes (Molenaar et al., 1996;
Logan andNusse, 2004). This pathway controls patterning
in the Xenopus embryo during cleavage stages, causing
the formation of the early embryonic dorsal axis (Harland,
2000; Heasman, 2006). At the gastrula stage, Wnts (and
LiCl) have the opposite effect, promoting the formation
of epidermis and ventral tissues (Figure S5B). Because
late Wnt signaling appeared to be mediated in part
through the regulation of Smad1 activity, we investigated
whether the late effects of Wnt signaling in Xenopus were
dependent on Tcf3 and b-Catenin. Dkk1 mRNA provides
an excellent reagent to explore this because it specifically
inhibits all gastrula-stage canonical Wnt signaling. Dkk1
greatly expands the anterior neural plate (Figure 7E0).
DN-Tcf3 encodes a 31 amino acid deletion lacking the
b-Catenin binding site (Molenaar et al., 1996), which
once bound to DNA blocks early Wnt signaling, resulting
in embryos devoid of neural plate (Figures 7E and 7F).
Remarkably, it was found that Dkk1 mRNA was able to
restore neural plate development in 60% of these em-
bryos (Figure 7F0). We also investigated whether the loss
of neural plate caused by depletion of b-Catenin could
be rescued byDkk1 and found, to our surprise, a complete
requirement for b-Catenin (Figures 7G and 7G0). We con-
clude from these epistatic experiments that Wnt signaling
promotes epidermal development via a Smad-dependent
pathway and that Dkk1 promotes neural development in
a Tcf-independent, yet b-Catenin-dependent, manner.
DISCUSSION
We investigated the function of the four conserved GSK3
phosphorylation sites in Smad1. During the course of the
work, we generated new phospho-specific antibody re-
agents for pSmad1MAPK and pSmad1GSK3 that revealed
a cell biological pathway by which the duration of the
BMP signal is exquisitely modulated. Three novel obser-
vations were made. First, we found that BMP signaling
triggers three sequential Smad1 phosphorylations by
BMPR, MAPK, and GSK3. Second, we found that the
GSK3 and MAPK phosphorylations specifically regulate
the duration of the BMP signal. Finally, experiments in cul-
tured mammalian cells and in Xenopus embryos indicated
that Smad1 phosphorylation by GSK3 serves to integrate
the BMP and Wnt signaling pathways.
Sequential Smad1 Phosphorylations
GSK3 phosphorylation required priming by phosphory-
lated MAPK sites located in the linker region of Smad1.
GSK3 phosphorylation-resistant mutations generated hy-
peractive forms of Smad1, as in the case of MAPK-990 Cell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc.resistant mutations (Kretzschmar et al., 1997; Pera et al.,
2003; Aubin et al., 2004; Sapkota et al., 2007). High-titer
phospho-specific antibody reagents for GSK3 (Ser210)
and MAPK (Ser214) revealed the biochemical pathway
of sequential phosphorylations summarized in Figure 5A.
C-terminal phosphorylation by BMPR triggered nuclear
translocation (Shi and Massague´, 2003) and was followed
about 30 min later by phosphorylation at MAPK sites, pre-
sumably in the nucleus. This served as priming for phos-
phorylation by GSK3. The intracellular site of the GSK3
phosphorylation is not known because GSK3 is found
both in nucleus and cytoplasm (Huang et al., 2007). The
combination of both MAPK and GSK3 phosphorylations
is essential for the polyubiquitinylation of Smad1 by the
Smurf1 E3 ubiquitin ligase (Zhu et al., 1999). Recently,
an independent study showed that MAPK phosphoryla-
tion is essential for Smad1 polyubiquitinylation (Sapkota
et al., 2007), a discovery fully confirmed here. One differ-
ence between the two studies is that here we report an
essential requirement for GSK3 for polyubiquitinylation
in vivo, whereas Sapkota et al. (2007) found only a partial
impairment in their in vitro studies. The broad theme that
emerges from these complementary studies is that linker
phosphorylations are required for Smad1 polyubiquitiny-
lation in a negative feedback loop (Sapkota et al., 2007;
this work).
Triply phosphorylated Smad1 is polyubiquitinylated,
binds to cytoplasmic microtubule-like filaments, and is
transported to the centrosome (Figure 4). The centrosome
has been described as the proteolytic center of the cell
(Badano et al., 2005). Inhibition of the proteolytic activity
of proteasomes with lactacystin caused a marked accu-
mulation of phospho-Smad1 destined for degradation
specifically in the centrosome. Because, as demonstrated
here, total polyubiquitin chains also accumulate in the
centrosome after lactacystin treatment, many other pro-
teins targeted for degradation must also use this pathway.
The study of Smad1 has led to the identification of an elab-
orate cellular pathway involved in the degradation of this
transcription factor.
The Duration of the Smad1 Signal Is Regulated
by a Cellular Proteolytic Pathway
Smad1 is a transcriptional activator that controls the activ-
ity of hundreds of downstream target genes (Shi and Mas-
sague´, 2003; Feng and Derynck, 2005). During signaling, it
is important to control both the intensity and the duration
of the signal. The classic example is provided by PC12
cells, in which a transient stimulus of MAPK/Erk by EGF
causes cell proliferation, whereas the more sustained ac-
tivation of Erk caused by NGF induces neuronal differenti-
ation and neurite outgrowth (Marshall, 1995). Whereas the
intensity of the Smad1 signal is determined by the dose of
BMP, its duration is regulated by the coupled phosphory-
lationsmediated byMAPK and GSK3. Thus, the half-life of
phospho-Smad1Cter was prolonged in pulse-chase exper-
iments by inhibiting the three main endogenous MAPKs
(Erk, p38, and JNK), GSK3, or proteasomal degradation
(Figure 3). This novel biochemical pathway offers rich pos-
sibilities for the differential regulation of target genes by
the Smad1 signal.
Integrating the A-P and D-V Axes
via Smad1 Phosphorylations
In Xenopus, the D-V axis is regulated by a gradient of BMP
maximal in the ventral and lowest in the dorsal, and the
A-P axis by a gradient of Wnt lowest in the head and high-
est in the posterior blastopore where xWnt8 is expressed
(Niehrs, 2004). When normal patterning is challenged by
transplanting a new organizer or cutting the embryo in
half, the new pattern is seamlessly integrated (De Robertis,
2006). The model shown in Figure 7H indicates how a self-
regulating patterning mechanism may integrate the A-P
and D-V axes. This model is based on recent studies on
BMP signals and their antagonists (Reversade and De
Robertis, 2005; Lee et al., 2006). Smad1/5/8 are presented
as key players that can transcriptionally activate ventral
genes (BMP4, the protease Xolloid-related, and its inhibitor
Sizzled) as well as xWnt8. Previous work has shown that
BMP4 is required for the expression of xWnt8, whereas
xWnt8 does not affect BMP4 levels in the Xenopus gastrula
(Hoppler andMoon, 1998). On the dorsal side, BMP signals
inhibit the transcription of genes such as ADMP (a dorsal
BMP-like molecule), Chordin, and Dkk1. The additional
layer of regulation of Smad1/5/8 by MAPKs activated by
RTKs such as FGFR, IGFR, and EGFR was not included
for simplicity. The key new node of interaction in this mod-
ified patterning network is that Wnt8 inhibits the phosphor-
ylation of Smad1 by GSK3, resulting in a longer BMP signal
which, in turn, is inhibited byDkk1. In this view, the D-V axis
would be specified by the intensity of the BMP signal and
the A-P positional information by its duration.
Our model proposes that Wnt enhances the BMP/
Smad1 signal. Such a molecular pathway could have
implications for the pathogenesis of hereditary bone dis-
eases. BMPs were isolated as potent inducers of bone
morphogenesis, yet recent genetic studies in humans
andmice have shown that the Wnt coreceptor LRP5 plays
a central role in bone mineralization. Loss-of-function
mutations in LRP5 cause osteoporosis and gain-of-func-
tion mutations cause osteopetrosis (reviewed in Koay
and Brown, 2005). Conversely, heterozygosity of Dkk1,
an LRP5/6 inhibitor, causes excessive bone mass forma-
tion (Morvan et al., 2006). Like Dkk1, Sclerostin (SOST) is
a Wnt antagonist that binds to LRP5/6 and leads to in-
creased bone mass in loss-of-function mutations (Seme-
nov et al., 2005). It would be interesting to determine
whether these osteoblast differentiation syndromes are
caused by misregulation of the duration of the Smad1/5/
8 signal through the Wnt/GSK3 pathway.
The canonical Wnt pathway can inhibit GSK3 activity
causing b-Catenin stabilization (Logan and Nusse, 2004).
Wnt3a protein moderately decreased pSmad1GSK3 levels
while increasing the activated pSmad1Cter form (Figure 5).
In cytological analyses, activation of the Wnt pathway by
a CA-LRP6 caused a striking change. The pSmad1GSK3Cantigen lost its centrosomal localization and was detected
in intracellular puncta corresponding to the recently
discovered LRP6 signalosomes that contain GSK3 and
other components of the Wnt-regulated protein degrada-
tion complex (Bilic et al., 2007). In addition, pSmad1GSK3
levels in the nucleus increased in cells transfected
with CA-LRP6. This redistribution from the centrosome
into putative signalosomes explains the residual levels of
pSmad1GSK3 found in Wnt-treated cells. Relocation of
GSK3 away from the cellular proteolytic center located
in the centrosomemay disrupt the flow of Smad1 targeted
for degradation and suffice to explain the stabilization of
pSmad1Cter caused by Wnt3a protein, as well as the
increase of pSmad1GSK3 levels in the nucleus. Perhaps
other features of the canonical Wnt/GSK3 pathway,
such as the stabilization of b-Catenin, are mediated by
the relocation of Wnt-regulated protein destruction com-
plexes away from the centrosomal proteasomes (Bilic
et al., 2007).
The new Wnt signaling branch identified here requires
Smad1 and is independent of Tcf3, yet requires b-Catenin
(Figure 7). This requirement suggests that both b-Catenin
and Smad1 might be degraded by a common Wnt-regu-
lated destruction complex containing GSK3, Axin, and
other components (Logan and Nusse, 2004). In this
regard, we note that b-Catenin has a primary structure re-
lated to armadillo domain adaptor proteins and may help
carry Smad1, and perhaps other proteins, to their destruc-
tion. A direct interaction between Smad4 and b-Catenin
has been reported (Nishita et al., 2000). In addition, b-Cat-
enin binds to the microtubular motor Dynein (Ligon et al.,
2001) and b-Catenin can localize to microtubules (Huang
et al., 2007). An attractive working hypothesis is that the
destruction of b-Catenin could serve to drive the flow of
Smad1 targeted for degradation to the centrosome. In
Drosophila, work currently under completion supports
the view that Wingless can stabilize the Mad transcription
factor (E.E., L.C.F., J. Clemens, and E.M. De R., unpub-
lished data). With 1500 transcription factors in the human
genome, one might predict that in future the degradation
of other proteins may also be found to be stabilized by
Wnt/GSK3 signaling.
EXPERIMENTAL PROCEDURES
Mammalian Cell Culture Experiments
Mouse L fibroblasts, Cos7, and HEK293T cells were cultured in DMEM
supplemented with 10% fetal bovine serum (GIBCO) and cultured at
37C in 5%CO2. For pulse-chase experiments, L cells were incubated
in serum-free medium (1/3 Iscove’s, 2/3 F12 DMEM, GIBCO) for 4 hr,
and 5 nMBMP7 added for 15min. Chemical inhibitors were added 1 hr
prior to the BMP7 pulse. Wnt3a protein (R&D Systems) was added at
300 ng/ml in the absence of serum. FGF-2 (Invitrogen) and BMP4
(R&D Systems) were added at 40 ng/ml and 0.3 nM, respectively.
CA-LRP6 (LRP6-DN, Tamai et al., 2004) was transfected into Cos7
cells with Fugene HD (Roche). We note that the pericentrosomal region
is best visualized in sparse cell cultures well below confluence at the
G1 phase. Ubiquitination assays were performed as described by
Zhu et al. (1999).ell 131, 980–993, November 30, 2007 ª2007 Elsevier Inc. 991
Western Blots and Immunostainings
Western blots of endogenous proteins were as described (Kuroda
et al., 2005), with polyclonal rabbit antibodies against pSmad1MAPK
(1:30,000), pSmad1GSK3-A (1:15,000), pSmad1Cter (1:1000; Cell Sig-
naling), and total Smad1 (1:1000; Zymed). b-catenin antibody (Sigma,
1:8000), GSK3b antibody (BD Transduction Labs, 1:1000), anti-His
antibody (Santa Cruz, 1:1000), and anti-flag-HRP conjugate (Sigma,
1:1500) were also utilized. Synthetic peptide was used to immunize
two rabbits (Covance). A second pSmad1GSK3 antibody phosphory-
lated at site 210 (designated B) that works on Western blots was
generated. For cell immunostaining, primary antibodies were used
as follows: pSmad1MAPK (1:2500), pSmad1GSK3 (1:1500), total polyubi-
quitin (1:500, Biomol), proteasome 20Sa5 subunit (1:200, Abcam),
g-Tubulin (1:500, Sigma), and Pericentrin (1:1000, Abcam). For
additional immunostaining methods, see Supplemental Experimental
Procedures.
In Vitro Phosphorylations
His-tagged linker region (residues 146–264) of Smad1 was cloned in
the periplasmic expression vector pET26b, expressed in E. coli BL21
cells, and purified with His Bind Resin (Novagen). The priming reaction
was performed for 40 min at 30C in kinase buffer (8 mM MOPS
[pH 7.3], 0.2 mM EDTA, 10 mMMgCaH3PO4, and 20 mMMgCl2) con-
taining 1mMcold ATP and 5 U/ml recombinant p42/Erk2 (New England
Biolabs). After heat inactivation of Erk (65C for 20 min), a second
reaction containing [g-32P]ATP (Amersham) and recombinant GSK3b
(Upstate) was performed for 1 hr at 30C.
Xenopus Microinjections
All microinjections were four times marginal (or in the animal pole for
ectodermal explants) at the 4-cell stage. Amounts injected per blasto-
mere were as follows: Xwnt8 MO (10 ng; Lee et al., 2006), ADMP-MO
(8.5 ng), b-catenin-MO (11 ng at 2-cell stage), pCSKA-Wnt8 DNA
(30 pg, Christian and Moon, 1993), pCS2-LRP6 DNA (10 pg, Tamai
et al., 2004), DN-xTCF3 mRNA (200 pg, Molenaar et al., 1996),
DN-Smad5 mRNA (100 pg, Beck et al., 2001), Dkk1 mRNA (50 pg
per embryo, Glinka et al., 1998), xBMP4 mRNA (50 pg), hSmad1
mRNA or its linker mutants (375 ng), and the constitutively active phos-
pho-mimetic hSmad1 SEVE or its linker mutants (200 pg). Luciferase
assays were as described in Kuroda et al. (2005). For quantitative
PCR, RNA was isolated with Absolutely RNA preparation kit (Strata-
gene), DNase treated, and reverse transcribed with random primers.
SYBR Green real-time quantitative PCR was performed in a MX3000
Cycler (Stratagene). Methods for mRNA synthesis, whole-mount in
situ hybridizations, and PCR primers are available at http://www.
hhmi.ucla.edu/derobertis/index.html.
Supplemental Data
Five figures and Experimental Procedures are available at http://www.
cell.com/cgi/content/full/131/5/980/DC1/.
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